Candriam SCA’s Nuvalent NUVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$40.1M Buy
391,306
+33,293
+9% +$3.39M 0.21% 105
2025
Q4
$36M Buy
358,013
+28,292
+9% +$2.79M 0.18% 125
2025
Q3
$28.5M Buy
329,721
+28,462
+9% +$2.25M 0.15% 138
2025
Q2
$23M Sell
301,259
-52,870
-15% -$3.87M 0.13% 148
2025
Q1
$25.1M Sell
354,129
-13,966
-4% -$1.09M 0.16% 136
2024
Q4
$28.8M Buy
368,095
+49,728
+16% +$4.64M 0.17% 123
2024
Q3
$32.6M Buy
318,367
+56,359
+22% +$4.67M 0.19% 118
2024
Q2
$19.9M Sell
262,008
-22,001
-8% -$1.56M 0.12% 170
2024
Q1
$21.3M Buy
284,009
+4,000
+1% +$318K 0.14% 158
2023
Q4
$20.6M Sell
280,009
-70,008
-20% -$4.33M 0.14% 157
2023
Q3
$16.1M Buy
350,017
+70,001
+25% +$3.11M 0.11% 171
2023
Q2
$11.8M Sell
280,016
-43,835
-14% -$1.66M 0.09% 224
2023
Q1
$7.78M Buy
323,851
+65,202
+25% +$1.93M 0.05% 294
2022
Q4
$7.7M Buy
+258,649
New +$7.21M 0.05% 316

Other funds holding NUVL

Candriam SCA's NUVL Position: Q1 2026 in Review

Candriam SCA increased its Nuvalent (NUVL) stake by 9.3% in Q1 2026, buying an estimated $3.39M and bringing the position to 391,306 shares worth $40.1M. The position accounts for 0.21% of the portfolio, ranked #105.

Candriam SCA first reported a position in NUVL in Q4 2022 and has held it in 14 quarters since. 263 funds tracked by Wall St. Rank hold NUVL as of Q1 2026.

  • Candriam SCA held 391,306 shares of Nuvalent worth $40.1M as of Q1 2026.
  • Candriam SCA bought 33,293 Nuvalent shares in Q1 2026, an estimated $3.39M.
  • Nuvalent made up 0.21% of Candriam SCA's portfolio in Q1 2026, its #105 holding.
  • Candriam SCA first reported a position in Nuvalent in Q4 2022 and has held it in 14 quarters since.
  • 263 funds tracked by Wall St. Rank held Nuvalent as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.